Literature DB >> 15529024

C-reactive protein as a risk factor versus risk marker.

Moniek Pm de Maat1, Astrid Trion.   

Abstract

PURPOSE OF REVIEW: C-reactive protein (CRP) is consistently associated with cardiovascular disease in prospective and cross-sectional clinical and epidemiological studies. Inflammation is an important mechanism in cardiovascular disease, and the plasma level of CRP is considered to reflect the inflammatory condition of the patient and/or the vessel wall. In addition, there are also a number of indications for a causal role of CRP in cardiovascular disease. RECENT
FINDINGS: A number of new publications show potential causal effects of CRP on cardiovascular disease, and evidence from human-CRP transgenic animals also indicates a causal contribution of CRP to cardiovascular disease. On the other hand, a new large prospective study and an updated meta-analysis indicate that the contribution of CRP to cardiovascular disease is less impressive than reported earlier (odds ratio, 1.58; 95% confidence interval, 1.48-1.68).
SUMMARY: We review here the most recent evidence on mechanisms by which CRP is involved as a causal factor in the precipitation of cardiovascular disease. Evidence for such a role is accumulating.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529024     DOI: 10.1097/00041433-200412000-00005

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  13 in total

1.  Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself.

Authors:  Mark B Pepys; Philip N Hawkins; Melvyn C Kahan; Glenys A Tennent; J Ruth Gallimore; David Graham; Caroline A Sabin; Arturo Zychlinsky; Juana de Diego
Journal:  Circ Res       Date:  2005-10-27       Impact factor: 17.367

Review 2.  Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions.

Authors:  Mark D DeBoer
Journal:  Nutrition       Date:  2012-09-28       Impact factor: 4.008

3.  Effect of supplementation with B vitamins and antioxidants on levels of asymmetric dimethylarginine (ADMA) and C-reactive protein (CRP): a double-blind, randomised, factorial design, placebo-controlled trial.

Authors:  Mark G O'Doherty; Sarah E C M Gilchrist; Ian S Young; Michelle C McKinley; John W G Yarnell; K Fred Gey; Alun Evans; Paula M L Skidmore; Jayne V Woodside
Journal:  Eur J Nutr       Date:  2010-04-18       Impact factor: 5.614

4.  Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study.

Authors:  Jian Shen; Chao-Qiang Lai; Josiemer Mattei; Jose M Ordovas; Katherine L Tucker
Journal:  Am J Clin Nutr       Date:  2009-12-02       Impact factor: 7.045

Review 5.  Carotid plaque, stroke pathogenesis, and CRP: treatment of ischemic stroke.

Authors:  Jerzy Krupinski; Marta M Turu; Mark Slevin; José Martínez-González
Journal:  Curr Cardiol Rep       Date:  2008-02       Impact factor: 2.931

Review 6.  Genetic determinants of C-reactive protein.

Authors:  Jacqueline Suk Danik; Paul M Ridker
Journal:  Curr Atheroscler Rep       Date:  2007-09       Impact factor: 5.113

7.  Carotid plaque, stroke pathogenesis, and CRP: treatment of ischemic stroke.

Authors:  Jerzy Krupinski; Marta M Turu; Mark Slevin; José Martínez-González
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06

8.  C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies.

Authors:  Jennifer K Pai; Kenneth J Mukamal; Kathryn M Rexrode; Eric B Rimm
Journal:  PLoS One       Date:  2008-01-02       Impact factor: 3.240

9.  Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study.

Authors:  Mika Kivimäki; Debbie A Lawlor; George Davey Smith; Meena Kumari; Ann Donald; Annie Britton; Juan P Casas; Tina Shah; Eric Brunner; Nicholas J Timpson; Julian P J Halcox; Michelle A Miller; Steve E Humphries; John Deanfield; Michael G Marmot; Aroon D Hingorani
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

10.  Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.

Authors:  Mark B Pepys; J Ruth Gallimore; Joanne Lloyd; Zhanhong Li; David Graham; Graham W Taylor; Stephan Ellmerich; Palma P Mangione; Glenys A Tennent; Winston L Hutchinson; David J Millar; Gary Bennett; John More; David Evans; Yogesh Mistry; Stephen Poole; Philip N Hawkins
Journal:  J Immunol Methods       Date:  2012-07-31       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.